Trial Profile

A Phase I/II Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of HB0028 in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HB 0028 (Primary)
Indications Adenocarcinoma; Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Liver cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Renal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors Huabo Biopharm

Most Recent Events

04 Jun 2024 Results (data cutoff date of DEC 25,2023, n= 16 patients) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
30 Jan 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com